Precision medicine for prostate cancer—improved outcome prediction for low-intermediate risk disease using a six-gene copy number alteration classifier

A multiplex 6-gene copy number classifier was used to distinguish between low- or intermediate-risk prostate cancer patients. The study analysed a cohort of 448 patients and previously published datasets from radical prostatectomies. The classifier performs better than conventional stratification methods, is low cost, and can be performed easily in clinical laboratories.